These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
77 related items for PubMed ID: 32042260
1. Comparative evaluation of biphasic insulin with metformin and triple oral hypoglycemic agents (OHA) in type 2 diabetes patients. Alavudeen SS, Khobrani M, Dhanapal CK, Mir JI, Alshahrani SM, Khan NA, Alhossan A. Saudi Pharm J; 2020 Feb; 28(2):210-214. PubMed ID: 32042260 [Abstract] [Full Text] [Related]
2. Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea. Bergenstal R, Lewin A, Bailey T, Chang D, Gylvin T, Roberts V, NovoLog Mix-vs.-Exenatide Study Group. Curr Med Res Opin; 2009 Jan; 25(1):65-75. PubMed ID: 19210140 [Abstract] [Full Text] [Related]
5. Treatment intensification in type 2 diabetes management after the failure of two oral hypoglycemic agents: A non-interventional comparative study. Shaik Alavudeen S, Alshahrani SM, Vigneshwaran E, Abdulla Khan N, Mir JI, Hussein ATM. Int J Clin Pract; 2021 Mar; 75(3):e13802. PubMed ID: 33112452 [Abstract] [Full Text] [Related]
7. [Identification of factors predicting early evolution of secondary oral hypoglycaemic agent failure and evaluation of clinical standards applied by primary care physicians during qualification to insulin therapy of patients with type 2 diabetes]. Machoy M. Ann Acad Med Stetin; 2004 Mar; 50(2):29-39. PubMed ID: 16529163 [Abstract] [Full Text] [Related]
11. Effect of bromocriptine-QR therapy on glycemic control in subjects with type 2 diabetes mellitus whose dysglycemia is inadequately controlled on insulin. Chamarthi B, Cincotta AH. Postgrad Med; 2017 May; 129(4):446-455. PubMed ID: 28374645 [Abstract] [Full Text] [Related]
13. Parameters measuring beta-cell function are only valuable in diabetic subjects with low body mass index, high blood glucose level, or long-standing diabetes. Lee SW, Lee S, Kim SH, Kim TH, Kang BS, Yoo SH, Lee MK, Koh WJ, Kang WS, Kim HJ. Yonsei Med J; 2011 Nov; 52(6):939-47. PubMed ID: 22028157 [Abstract] [Full Text] [Related]
16. Effects of replacing metformin with pioglitazone on glycemic control in japanese patients with poorly controlled type 2 diabetes mellitus: A 12-week, open-label, prospective study. Sakaue S, Kamigaki M, Yoshimura H, Nishimura M. Curr Ther Res Clin Exp; 2008 Aug; 69(4):364-77. PubMed ID: 24692813 [Abstract] [Full Text] [Related]
17. Eight weeks of treatment with long-acting GLP-1 analog taspoglutide improves postprandial insulin secretion and sensitivity in metformin-treated patients with type 2 diabetes. Gastaldelli A, Nauck MA, Balena R. Metabolism; 2013 Sep; 62(9):1330-9. PubMed ID: 23831441 [Abstract] [Full Text] [Related]
18. EADSG Guidelines: Insulin Therapy in Diabetes. Silver B, Ramaiya K, Andrew SB, Fredrick O, Bajaj S, Kalra S, Charlotte BM, Claudine K, Makhoba A. Diabetes Ther; 2018 Apr; 9(2):449-492. PubMed ID: 29508275 [Abstract] [Full Text] [Related]
19. Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study. Tîrgovişte CI, Străchinariu R, Farcaşiu E, Milicevic Z, Teodorescu G. Rom J Intern Med; 2003 Apr; 41(2):153-62. PubMed ID: 15526500 [Abstract] [Full Text] [Related]